The Peptide CDMOs — Making the GLP-1 Molecules
Every Ozempic shot started its life as a chain of 30+ amino acids assembled in a Swiss CDMO. Two companies dominate. They are sold out for years.
GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptides — short chains of amino acids manufactured by linking 30–40 building blocks together in a process called solid-phase peptide synthesis (SPPS). Each coupling cycle takes hours. The chemistry, scaled to multi-ton production, is dominated by a handful of contract development and manufacturing organizations (CDMOs). Bachem (Switzerland) is #1. PolyPeptide (Switzerland) is #2. Lonza is a much larger generalist CDMO with peptide capability. All are sold out through multi-year contracts.
Capacity expansion takes 3–5 years from groundbreaking to FDA approval of the new line. Demand is exploding. Even with Novo Nordisk and Eli Lilly building in-house capacity, the merchant peptide CDMO market is sold out for years.
3 names on the watchlist
#1 global peptide CDMO. Makes the API for Wegovy, Zepbound, and 88+ approved peptide drugs plus 267 in late-stage trials.
Swiss CDMO that develops and manufactures peptides (and oligonucleotides) at GMP scale for pharma customers . The single most important supplier in the GLP-1 supply chain. Largest commercial-scale third-party peptide CDMO globally. Each GLP-1 peptide requires 30–40 SPPS coupling cycles. Capacity expansion underway at Bubendorf "Building K," Vista CA (~1 metric ton/year), St Helens UK, and a new Sisseln site.
#2 global peptide CDMO. €100M Malmö SPPS expansion underway.
Swiss #2 peptide CDMO behind Bachem. Smaller, more turnaround-focused. €100M Malmö SPPS expansion underway. Higher beta way to play the same GLP-1 thesis with more upside if execution holds — but also more downside if customers concentrate orders at Bachem.
Largest CDMO globally — small molecules, biologics, cell/gene, peptides. Broader exposure than pure-play peptide names.
Largest CDMO globally — handles small molecules, biologics, cell/gene therapy, and peptides for pharma customers. FY26 sales growth confirmed at 11–12%. Lower-beta diversified way to own the picks-and-shovels theme without single-peptide concentration. Less GLP-1 leverage but more growth durability.
- Fortune Business Insights, Precedence Research · 2025–2026